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nucleos/tide analogues such as tenofovir or entecavir, with a high
genetic barrier, those conclusions enlighten the fact that assess-
ment of patient adherence to antiviral treatment has to be
addressed every time a suboptimal response is observed. In this
setting, antiviral drug dosing should then be considered as a
meaningful tool. Promoting persistence of on-therapeutic adher-
ence motivation in this life long treatment setting is fundamen-
tal. As described with other chronic diseases, especially HIV,
speciﬁc therapeutic educational programs are to be developed
after a proper assessment of the true determinants of patient
adherence.
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Reply to: ‘‘Does adherence to hepatitis B antiviral treatment
correlate with virological response and risk of breakthrough?’’
JOURNAL OF HEPATOLOGYTo the Editor:
We are delighted that Dr. Hilleret and colleagues concur with
our ﬁnding that in real life clinical practice, adherence to
nucleos(t)ide analogs for hepatitis B is less than ideal and
has a tendency to decline with time. We agree that the major
limitation of our study [1] is the inability to correlate our ﬁnd-
ings with clinical data, but utilizing a nationwide pharmacy
database enabled us to study a large number of patients in
the community that are more representative than a small
cohort of patients in a single tertiary referral center. We con-
gratulate Dr. Hilleret and colleagues in utilizing a direct mea-
sure of adherence – serum concentrations of the medication
administered, in this case adefovir. We are pleased to see that
Dr. Hilleret and colleagues demonstrated a correlation between
undetectable concentrations of adefovir in serum and lower
rate of virologic response. In a retrospective study of 148
patients receiving nucleos(t)ide analogs for chronic hepatitis B
in our clinic, we found that 39 patients had at least one viro-
logic breakthrough during a mean follow-up of 37.5 months
[2]. However, only 24 patients had genotypic resistance. Of
the 10 patients who experienced virologic breakthrough that
was not conﬁrmed on retesting, all 10 had further decrease
in serum HBV DNA and nine had undetectable HBV DNA dur-Journal of Hepatology 201ing continued treatment with the same medications. Although
adherence was not assessed in that study, these data suggest
that medication non-adherence is a common cause of transient
virologic breakthrough. Our ﬁndings and those of Dr. Hilleret
and colleagues highlight the importance of counseling patients
with chronic hepatitis B receiving nucleos(t)ide analogs on
medication adherence to achieve optimal responses.
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Modulation of the effect of PNPLA3 I148M mutation on steatosis
and liver damage by alcohol intake in patients with chronic hepatitis C
To the Editor:
The Patatin-like phospholipase domain-containing-3 (PNPLA3)
rs738409 polymorphism, encoding for the I148M protein variant,
is a strong genetic determinant of hepatic fat accumulation and
progressive alcoholic as well as nonalcoholic steatohepatitis in
adults and children [1–4], explaining almost a quarter of cirrhosis
variability in alcoholic liver disease [5]. We and others [6,7] have
demonstrated that in patients with chronic hepatitis C (CHC), this
genetic factor inﬂuences steatosis development in nongenotype 3
patients, the progression of liver damage, and susceptibility to
develop cirrhosis and its complications [8] (Table 1).
Muller et al. have very recently replicated the association of
the PNPLA3 148M polymorphism with steatosis and cirrhosis in
an independent cross-sectional study in German patients with
CHC [9]. Interestingly, there was a signiﬁcantly higher preva-
lence of subjects who consumed a moderate, but potentially
harmful, intake of alcohol in this series than in that described
in our paper, and a distinct effect of the 148M polymorphism
on steatosis and liver damage according to the amount of daily
alcohol intake could be observed, in that homozygosity for the
148M was associated with steatosis only in abstainers, whereas
it was associated with cirrhosis only in at risk drinkers. These
data led the authors to hypothesize that PNPLA3 genotype
may exert a differential effect on liver damage according to
alcohol consumption.
As the mechanisms underpinning the detrimental effect of the
148M PNPLA3 variant in a rapidly widening range of liver dis-
eases is still unknown, to contribute elucidating this issue we
have now replicated the same analyses in our series of patients
subdivided according to alcohol intake, and provide a pooled esti-
mate of the effect of the 148M on the risk of steatosis and cirrho-
sis in the two combined studies.
Although the effect of PNPLA3 genotype might be more evi-
dent when considering more severe steatosis [2,7], pooled
results conﬁrm that in CHC the 148M polymorphism is associ-
ated with the presence of steatosis only in ‘‘abstainers’’ (<30 g
alcohol/day), possibly because of the confounding effect of
alcohol in moderate drinkers, but, on the contrary, is signiﬁ-
cantly associated with cirrhosis both in abstainers and in mod-
erate drinkers, and the effect seems more marked in those who
consume more than 30 g alcohol/day, as suggested by Muller
et al. [9]. Thus, as previously suggested [2], the detrimental
effect of the 148M PNPLA3 variant on the progression of liver
damage might not be limited to predisposition to steatosis
development.
The discrepant results obtained in our series, as reﬂected by the
signiﬁcant heterogeneity observed between the two studies for the
effect of at risk drinking on cirrhosis, may be due to the relatively
small number of drinkers in Italianpatients, or to other unmeasured
confounders, such as additional genetic [10] andenvironmental fac-
tors, and possibly the prevalence of occult HBV infection.
Nevertheless, these results indicate that additional studies are
warranted to analyze the interaction between even moderate
amounts of alcohol and PNPLA3 genotype in liver diseases.
Table 1. Logistic regression analysis and meta-analysis results for the association of PNPLA3 rs738409 SNP (I148M), under a recessive inheritance model, with the
presence of steatosis and cirrhosis according to daily alcohol intake in 819 previously described Italian patients [7] and 494 German patients [9] with CHC.
Italian CHC German CHC Pooled data
Steatosis OR (95% CI) OR (95% CI) OR (95% CI)
Total 1.82 (1.33-2.58) n = 819 5.53 (1.55-19.8) n = 442 1.95 (1.43-2.67) n = 1261
Abstainers 1.84 (1.33-2.65) n = 724 12.6 (1.48-108) n = 235 1.93 (1.38-2.69) n = 959
At risk drinkers 1.30 (0.49-5.83) n = 95 2.61 (0.50-13.5) n = 207 1.67 (0.63-2.41) n = 302
Cirrhosis OR (95% CI) OR (95% CI) OR (95% CI)
Total 1.30 (1.01-1.66) n = 819 2.76 (1.22-6.25) n = 605 1.38 (1.10-1.75) n = 1424
Abstainers 1.39 (1.06-1.81) n = 724 1.65 (0.54-5.03) n = 335 1.40 (1.09-1.81) n = 1059
At risk drinkers 0.89 (0.37-1.94) n = 95 4.77 (1.39-6.38) n = 270 2.20 (1.28-3.80)* n = 365
OR: odds ratio for the presence of homozygosity for the 148M PNPLA3 variant, adjusted for age, sex, BMI, and, only for steatosis, viral genotype 3, as in [9]. c.i.: Conﬁdence
interval. Steatosis: grade 1–3 vs. grade 0. Cirrhosis: Ishak stage 5–6 vs. 0–4. Abstainers: <30 g/day; at risk drinkers: P20 g/day, as in [9].
Pooled estimates (OR, 95% c.i.) were calculated by the inverse variance method (ﬁxed effect model) by the Review Manager v.5 software (cochrane collaboration). ⁄p <0.05
for heterogeneity between studies.
Letters to the Editor
1470 Journal of Hepatology 2011 vol. 55 j 1467–1472
